Skip to main content

Advertisement

SpringerLink
Log in

HER2 Blockade: Is Combination Therapy Better Than Monotherapy?

  • Clinical Trials Report
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Geyer C, Forster J, Lindquist D, et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Eng J Med 2006, 355:26–32.

    Article  Google Scholar 

  2. Di Leo A, Gomez H, Aziz Z, et al.: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008, 26:5544–5552.

    Article  CAS  PubMed  Google Scholar 

  3. von Minckwitz G, du Bois A, Schmidt M, et al.: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer. J Clin Oncol 2009, 27:1999–2006.

    Article  Google Scholar 

  4. Dang C, Lin N, Moy B, et al.: Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol 2010, 28:2892–2988.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rena Rowan Breast Center, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

    Rebecca L. Hirsh MD & Kevin R. Fox MD

Authors
  1. Rebecca L. Hirsh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin R. Fox MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin R. Fox MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hirsh, R.L., Fox, K.R. HER2 Blockade: Is Combination Therapy Better Than Monotherapy?. Curr. Treat. Options in Oncol. 11, 63–65 (2010). https://doi.org/10.1007/s11864-010-0125-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-010-0125-1

Keywords

Search

Navigation